Skip to main content

Table 6 Clinical features of LPT-positive and LPT-negative sarcoidosis patients

From: Immunoreactivity to metal and silica associates with sarcoidosis in Dutch patients

 

LPT-negative (%)

(n = 26)

LPT-positive (%)

(n = 7)

P*

Male / Female

92.3 / 7.7

85.7/ 14.3

0.52

Age at diagnosis (Y)

43.46 ± 11.61

41.40 ± 7.97

0.66

Time after diagnosis (Y)

13.65 ± 12.39

9.21 ± 8.21

0.36

Medication

46.2

42.9

1.00

Scadding stage at diagnosis (0/I/II/III/IV, unknown)

11.5/26.9/42.3/3.8/0/

15.4

0/42.9/28.6/0/14.3/

14.3

0.36

Scadding stage at inclusion (0/I/II/III/IV, unknown)

38.5/7.7/11.5/11.5/30.8/

0

28.6/14.3/14.3/0/28.6/

14.3

0.42

Extra pulmonary involvement

57.7

57.1

1.00

COS

n = 21

n = 5

 

Resolved & minimal disease

4.8

40

0.09

Persistent disease without therapy

33.3

20

1.00

Persistent disease with need for therapy

61.9

40

0.62

  1. Age at diagnosis and time after diagnosis are shown as means ± std. deviation. COS Clinical outcome status. COS was defined 5 years after diagnosis. Information to determine COS was missing for 7 patients (5 LPT-negative and 2 LPT positive patients).
  2. * Statistical differences for sex, medication, COS groups, extra pulmonary involvement, was accessed using Fisher’s Exact Test, P-values for scadding stages were calculated using Pearson Chi-Square. Statistical differences for age at diagnosis were calculated using an unpaired T-test and statistical differences for time after diagnosis was calculated using Mann-Whitney U test